CCTV’s Finance Channel provides an authoritative analysis: With the first Vaccine Administration Law now in effect, what improvements can we expect from domestically produced vaccines?

Release date:

2019-08-06

Author:

Source:


Abstract

Since the enactment of the Vaccine Administration Law, what impact will it have on China’s domestic vaccine industry? How are vaccine manufacturers preparing to comply with this new legislation? Recently, Miao Xiang, Secretary of the Board of Kangtai Biological, and Zhu Zhengyu, Head of Quality, were interviewed by CCTV’s Finance Channel. They outlined the company’s active participation in drafting the law, as well as specific measures to continuously enhance quality‑control standards and advance the development of innovative vaccine products. The program aired at 14:00 on July 31. https://mp.weixin.qq.com/s/-51NzRBQWkx2yGlrjhzIfQ

  Since the enactment of the Vaccine Administration Law, what impact will it have on China’s domestic vaccine industry? How are vaccine companies preparing to comply with this new legislation? Recently, Miao Xiang, Secretary of the Board at Kintor Pharmaceutical, and Zhu Zhengyu, Head of Quality, were interviewed by CCTV’s Finance Channel. They outlined the company’s active participation in drafting the law, as well as its concrete measures to continuously enhance quality‑control standards and advance the development of innovative vaccine products. The program aired on July 31 at 2:00 p.m.

 

 

https://mp.weixin.qq.com/s/-51NzRBQWkx2yGlrjhzIfQ

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09